Sutro Biopharma, Inc. STRO

$8.92 -4.29% at last close
Market Cap$154.73 million
P/E Ratio—
Div Yield—
Volume210.5K
52-Week Range $7.15$43.85

Analyst Ratings

Consensus
Buy — 9 Buy · 0 Hold · 0 Sell (9 analysts)
Avg. Price Target
$47.33 (+430.6% upside)

Full STRO forecast & analyst actions →

Key Stats

Today's Range
$8.65 – $9.57
50-Day Range
$8.11 – $19.46
52-Week Range
$7.15 – $43.85
Volume
210K shs
Average Volume
337K shs
Market Cap
$154.73 million
P/E Ratio
—
Dividend Yield
—

Short Interest

Short Interest
0.07%
Days to Cover
1.00

About Sutro Biopharma, Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Employees
128
Exchange
XNAS
Listed
2018-09-27

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.